Clearmind Medicine Inc Faces Nasdaq Compliance Issue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 08 Dec 25
Clearmind Medicine Inc's share price fell by 8.52%, crossing down the 5-day SMA amid Nasdaq compliance issues.
On December 4, 2025, the company received a notice from Nasdaq regarding non-compliance with Listing Rule 5550(a)(2) due to its shares closing below $1 for 30 consecutive business days. The company has a 180-day compliance period to rectify this situation.
Failure to regain compliance could lead to delisting risks, impacting investor confidence and potentially affecting the company's financing capabilities and market reputation.
Analyst Views on CMND
About CMND
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
